Swiss drug manufacturer Novartis will acquire IFM Tre, a subsidiary of US firm IFM Therapeutics, for $310m, with potentially $1.3bn offered in milestone payments. IFM Tre is developing nonalcoholic steatohepatitis (NASH) therapy IFM-2427, a treatment aimed at fatty liver disease, which is becoming more common, alongside Type 2 diabetes and obesity, and could become the first to secure regulatory approval. The market for NASH drugs could be worth up to $21.5bn by last week, according to ResearchAndMarkets.com.
Swiss drug manufacturer Novartis will acquire IFM Tre, a subsidiary of US firm IFM Therapeutics, for $310m, with potentially $1.3bn offered in milestone payments. IFM Tre is developing nonalcoholic steatohepatitis (NASH) therapy IFM-2427, a treatment aimed at fatty liver disease, which is becoming more common, alongside Type 2 diabetes and obesity, and could become the first to secure regulatory approval. The market for NASH drugs could be worth up to $21.5bn by 2025, according to ResearchAndMarkets.com.